Stomach Cancer Exosome-based Detection

Study summary

Gastric cancer continues to have a poor prognosis primarily due to the inability to detect it in its early stages. This study will develop and validate a blood assay to facilitate the non-invasive detection of gastric cancer.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedDESTINEX

The study team can explain what participation involves.

Who it may be forEarly-stage or resectable · Locally advanced · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 8, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?3 U.S. locations

Locations may change over time.

Who runs it?City of Hope Medical Center

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: City of Hope Medical Center
Interventions being studied: Diagnostic Test: DESTINEX

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting

Early-stage or resectable→Locally advanced→Metastatic or stage IV→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Histological diagnosis of stage I, II, III, IV gastric cancer (TNM classification, 8th edition) (cases).
Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.
Confirmed cancer-free status at the time of study inclusion (Non-disease controls).

Reasons someone may not be able to joinExclusion criteria

Lack of written informed consent.
Systemic therapy before sampling.
Synchronous gastric and non-gastric cancer diagnosed at or before surgery.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

City of Hope Medical CenterDuarte, California
Nagoya UniversityNagoya
Mie UniversityTsu

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 8, 2024. Always confirm current availability with the study team.

View original record ↗